Thursday, August 20, 2020 11:19:06 AM
Trinity Biotech announces EUA submission for Covid-19 ELISA Antibody test
August 20 2020 - 10:31AM
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets announced that it has filed its submission for an Emergency Use Authorization (EUA) for its Covid-19 IgG ELISA antibody test with the FDA. This test will determine which individuals within the population have been exposed to the SARS-CoV-2 virus. The transfer of production to our facility in Jamestown, New York is complete, our manufacturing capability is very significant and the instrumentation platforms that perform ELISA testing are available in virtually every testing laboratory in the world.
The product demonstrates specificity in excess of 98% and sensitivity in excess of 95%, in samples of 14 days or more from symptom onset. EUA submission allows us to begin marketing the product immediately.
In addition, the Company is developing a rapid point-of-care Covid-19 test to detect antibodies to the virus that can be run in 12 minutes using one drop of blood procured by finger prick. This test will have utility similar to that outlined above for the ELISA antibody test. Once development and transfer to manufacturing of this rapid test is complete we intend to avail of the FDA’s EUA pathway to expedite its approval for sale in the USA.
This pipeline of Covid-19 products complements our existing Viral Transport Media (VTM) product, which is used in the Covid-19 sample collection process for PCR molecular testing. We have scaled up the manufacture of VTM to meet increased levels of demand over the past months and we expect demand to continue as Covid-19 testing remains critical to the management of the pandemic.
Ronan O’Caoimh, Chief Executive Offer commented “We are very pleased to announce the submission of our Covid-19 ELISA antibody test for FDA Emergency Use Authorization (EUA). The test demonstrates both impressive specificity and sensitivity. Meanwhile, the ELISA testing platform with its excellent reputation for quality and widespread adoption makes it an ideal format for large scale antibody testing.”
Recent TRIB News
- Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development • GlobeNewswire Inc. • 05/08/2024 02:36:58 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:26 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/07/2024 08:25:53 PM
- Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates • GlobeNewswire Inc. • 04/04/2024 11:30:02 AM
- Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 10:39:07 PM
- Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 03/08/2024 03:03:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/15/2024 07:11:36 PM
- Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change • GlobeNewswire Inc. • 02/15/2024 05:34:50 PM
- Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change • GlobeNewswire Inc. • 02/13/2024 02:00:12 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/10/2024 12:51:28 AM
- Trinity Biotech to Present at Emerging Growth Conference • GlobeNewswire Inc. • 02/08/2024 01:30:00 PM
- Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:37:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:33:32 PM
- Trinity Biotech Announces Q3 2023 Financial Results & Business Update • GlobeNewswire Inc. • 01/31/2024 12:05:00 PM
- Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India • GlobeNewswire Inc. • 01/31/2024 12:02:00 PM
- Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc. • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Trinity Biotech plc to Host Investor Call • GlobeNewswire Inc. • 01/30/2024 10:23:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/02/2024 09:17:57 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/02/2024 09:13:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 07:02:39 PM
- Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya • GlobeNewswire Inc. • 12/27/2023 01:57:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 06:56:39 PM
- Trinity Biotech Announces Management Changes • GlobeNewswire Inc. • 12/18/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 02:00:03 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM